Comparative Pharmacology
Head-to-head clinical analysis: ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE versus HICON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE versus HICON.
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE vs HICON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Albuterol is a beta-2 adrenergic receptor agonist that relaxes bronchial smooth muscle. Ipratropium bromide is an anticholinergic agent that inhibits muscarinic receptors, reducing bronchoconstriction and mucus secretion.
Unknown; possibly involves modulation of hypothalamic thermoregulatory center.
Two inhalations (albuterol 90 mcg and ipratropium 18 mcg per inhalation) four times daily via oral inhalation. Maximum: 12 inhalations per day.
HICON (norepinephrine) 0.05-0.5 mcg/kg/min IV continuous infusion, titrated to blood pressure.
None Documented
None Documented
Albuterol: 3-6 hours (terminal half-life), prolonged in hepatic or renal impairment. Ipratropium: 1.5-2 hours (terminal half-life), clinical effects persist longer due to receptor binding.
Terminal half-life: 12-18 hours; prolonged to 24-36 hours in renal impairment (CrCl <30 mL/min)
Albuterol: 60-70% renal as unchanged drug and metabolites (primarily sulfate conjugate), 10-20% fecal. Ipratropium: 50-60% fecal (unabsorbed), 30-40% renal (metabolites); minimal renal excretion of unchanged drug.
Renal: 70% as unchanged drug; biliary/fecal: 25% as metabolites; 5% other
Category A/B
Category C
Anticholinergic
Anticholinergic